{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:41:40Z","timestamp":1793828500820,"version":"4.6.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we examined the details and outcomes of ASCT performed as first-line therapy in eligible Canadian MM patients between 2007 to 2021. We included 3821 patients with 72% receiving CyBorD induction and 2061 patients receiving maintenance, consisting of lenalidomide +\/- steroids in 78.3%. The median PFS and OS for patients given a single ASCT were 35.4 and 126\u2009months. Those receiving a second induction regimen had significantly inferior outcomes, although when maintenance was used, results were comparable regardless of the number of induction regimens administered (median PFS 55.3 vs 51.1\u2009months [\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.11]; median OS 158.6 vs not yet reached [\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.13]). Consolidation patients had a longer median PFS (55.3 vs 34.4\u2009months [\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001]), but no significant gain in median OS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.065). Patients who received lenalidomide-based maintenance experienced a median PFS of 53.7\u2009months and OS of 159\u2009months. In the multivariable analysis, use of any type of maintenance therapy vs no maintenance was associated with a lower risk of progression (HR 0.52 (95% CI 0.47-0.57)) and death (HR 0.58 (95% CI 0.51-0.67)). This real-world study demonstrates that, overall, first-line treatment sequence in transplant-eligible patients produces a median OS of \u226510\u2009years. It also highlights the contribution of post-ASCT maintenance, particularly lenalidomide given until progression.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00905-8","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:01:43Z","timestamp":1693890103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1383-2984","authenticated-orcid":false,"given":"Julie","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4368","authenticated-orcid":false,"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Masih-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stakiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Kaedbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3215","authenticated-orcid":false,"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u2013e468.","journal-title":"Lancet Haematol"},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JOP.19.00244","volume":"16","author":"A Branagan","year":"2020","unstructured":"Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. JCO Oncol Pract. 2020;16:5\u201314.","journal-title":"JCO Oncol Pract"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/leu.2017.83","volume":"31","author":"H Einsele","year":"2017","unstructured":"Einsele H, Knop S, Vogel M, M\u00fcller J, Kropff M, Metzner B, et al. Response-adapted consolidation with bortezomib after ASCT improves progression free survival in newly diagnosed multiple myeloma. Leukaemia. 2017;31:1463\u20136.","journal-title":"Leukaemia"},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda DB, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895\u2013905.","journal-title":"N Engl J Med"},{"key":"905_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-10-1925","volume":"17","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res. 2011;17:1253\u201363.","journal-title":"Clin Cancer Res"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, Holstein SA, Moreau P, Spada S, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018;4:1389\u201397.","journal-title":"JAMA Oncol"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3324\/haematol.2020.259093","volume":"106","author":"HM Cherniawsky","year":"2021","unstructured":"Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, et al. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. Haematologica. 2021;106:1733\u20136.","journal-title":"Haematologica."},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia."},{"key":"905_CR10","first-page":"3462","volume":"130","author":"C Yang","year":"2017","unstructured":"Yang C, Jiang H, Masih-Khan E, Chen CI, Prica A, Reece D, et al. Tolerability and efficacy of post-transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood. 2017;130:3462.","journal-title":"Blood."},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:1928\u201337.","journal-title":"J Clin Oncol"},{"key":"905_CR13","doi-asserted-by":"publisher","first-page":"8506.","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","volume":"38","author":"P Hari","year":"2020","unstructured":"Hari P, Pasquini MC, Stadtmauer EA, Fraser R, Fei M, Devine SM, et al. Long-term follow-up of BMTCTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation strategies in the upfront treatment of mutliple myeloma. J Clin Oncol. 2020;38:8506.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00905-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T07:03:31Z","timestamp":1700291011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00905-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00905-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. has received honoraria from Janssen and Sanofi, and research funding from Janssen. H.M. has received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK, and she also received the HHS Research Early Career Award from Hamilton Health Sciences Foundation. D.R. has received research funding from Otsuka, Celgene, Janssen, Takeda, Merck, BMS and Millennium, and she served as a consultant for Celgene, Jansen, Amgen, Karyopharm and Takeda. She also received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. A.M. has received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. V.H.J-Z. has received honoraria from Celgene, Janssen, Takeda, Merck and BMS. K.S. has received research funding from Celgene, and honoraria from Celgene, Janssen, Amgen and Takeda. M.L. has received honoraria from Janssen, Celgene, Amgen and Pfizer. R.L. served as a consultant for BMS, Janssen, Amgen, Sanofi and FORUS Therapeutics, and received honoraria from Pfizer. M.S. has a membership on an entity\u2019s Board of Directors or advisory committees for Janssen, Amgen, Takeda and Celgene. J.S. has received honoraria from Janssen, FORUS Therapeutics, BMS, Pfizer, Sanofi and Amgen. R.Ko. has received honoraria from Akcea, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer and Takeda, and research funding from Merck and Sanofi. He also declares a current equity holder in the private company Karyopharm. R.Ka. served as a consultant for Janssen, BMS, Sanofi, FORUS, Beigene and Pfizer, and has received honoraria from BMS and Janssen. D.W. has received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm, Sanofi and Takeda. C.V. has received honoraria from Janssen, Takeda, FORUS, BMS, Abbvie, Sanofi, GSK and Pfizer. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}